Targeted next-generation sequencing to assess tumor mutation burden: ready for prime-time in non-small cell lung cancer?
作者信息
Tomasini Pascale, Greillier Laurent
机构信息
Department of Multidisciplinary Oncology and Therapeutic Innovations, Assistance Publique Hopitaux de Marseille, Aix-Marseille University, Marseille, France.
Centre de Recherche en Cancérologie de Marseille (CRCM), Marseille, France.
出版信息
Transl Lung Cancer Res. 2019 Dec;8(Suppl 4):S323-S326. doi: 10.21037/tlcr.2019.09.01.
Abstract
摘要
相似文献
1
Targeted next-generation sequencing to assess tumor mutation burden: ready for prime-time in non-small cell lung cancer?靶向二代测序评估肿瘤突变负荷：非小细胞肺癌能否迎来黄金时代？
Transl Lung Cancer Res. 2019 Dec;8(Suppl 4):S323-S326. doi: 10.21037/tlcr.2019.09.01.
2
Comparison of EML4-ALK fusion gene positive rate in different detection methods and samples of non-small cell lung cancer.不同检测方法及非小细胞肺癌样本中EML4-ALK融合基因阳性率的比较
J Cancer. 2020 Jan 14;11(6):1525-1531. doi: 10.7150/jca.36580. eCollection 2020.
3
Molecular profiling of key driver genes improves staging accuracy in multifocal non-small cell lung cancer.多灶性非小细胞肺癌中关键驱动基因的分子谱分析提高了分期准确性。
J Thorac Cardiovasc Surg. 2020 Aug;160(2):e71-e79. doi: 10.1016/j.jtcvs.2019.11.126. Epub 2019 Dec 20.
4
Use of targeted next generation sequencing to characterize tumor mutational burden and efficacy of immune checkpoint inhibition in small cell lung cancer.利用靶向下一代测序技术来描述小细胞肺癌的肿瘤突变负担和免疫检查点抑制的疗效。
J Immunother Cancer. 2019 Mar 28;7(1):87. doi: 10.1186/s40425-019-0572-6.
5
Routine Clinical Mutation Profiling of Non-Small Cell Lung Cancer Using Next-Generation Sequencing.使用下一代测序技术对非小细胞肺癌进行常规临床突变分析
Arch Pathol Lab Med. 2015 Jul;139(7):913-21. doi: 10.5858/arpa.2014-0095-OA.
6
The long tail of molecular alterations in non-small cell lung cancer: a single-institution experience of next-generation sequencing in clinical molecular diagnostics.非小细胞肺癌中分子改变的长尾：单机构在临床分子诊断中进行下一代测序的经验。
J Clin Pathol. 2018 Sep;71(9):767-773. doi: 10.1136/jclinpath-2018-205032. Epub 2018 Mar 13.
7
Next-generation sequencing reveals novel resistance mechanisms and molecular heterogeneity in EGFR-mutant non-small cell lung cancer with acquired resistance to EGFR-TKIs.下一代测序揭示了 EGFR-TKI 获得性耐药的 EGFR 突变型非小细胞肺癌中的新型耐药机制和分子异质性。
Lung Cancer. 2017 Nov;113:106-114. doi: 10.1016/j.lungcan.2017.09.005. Epub 2017 Sep 12.
8
PD-L1 expression and tumor mutational burden status for prediction of response to chemotherapy and targeted therapy in non-small cell lung cancer.程序性死亡配体 1 表达和肿瘤突变负担状态预测非小细胞肺癌对化疗和靶向治疗的反应。
J Exp Clin Cancer Res. 2019 May 14;38(1):193. doi: 10.1186/s13046-019-1192-1.
9
Yield and Clinical Utility of Next-Generation Sequencing in Selected Patients With Lung Adenocarcinoma.下一代测序在部分肺腺癌患者中的产量及临床应用价值
Clin Lung Cancer. 2016 Nov;17(6):517-522.e3. doi: 10.1016/j.cllc.2016.05.017. Epub 2016 Jun 8.
10
Tag-based next generation sequencing: a feasible and reliable assay for EGFR T790M mutation detection in circulating tumor DNA of non small cell lung cancer patients.基于标签的下一代测序：一种可行且可靠的方法，可用于检测非小细胞肺癌患者循环肿瘤 DNA 中的 EGFR T790M 突变。
Mol Med. 2019 Apr 27;25(1):15. doi: 10.1186/s10020-019-0082-5.
引用本文的文献
1
The joint role of methylation and immune-related lncRNAs in ovarian cancer: Defining molecular subtypes and developing prognostic signature.甲基化与免疫相关长链非编码RNA在卵巢癌中的联合作用：定义分子亚型并建立预后特征
Transl Oncol. 2023 Aug;34:101704. doi: 10.1016/j.tranon.2023.101704. Epub 2023 May 29.
2
Peripheral lymphocyte count as a surrogate marker of immune checkpoint inhibitor therapy outcomes in patients with non-small-cell lung cancer.外周血淋巴细胞计数作为免疫检查点抑制剂治疗非小细胞肺癌患者疗效的替代标志物。
Sci Rep. 2022 Jan 12;12(1):626. doi: 10.1038/s41598-021-04630-9.
3
A novel model based on liquid-liquid phase separation-Related genes correlates immune microenvironment profiles and predicts prognosis of lung squamous cell carcinoma.一种基于液-液相分离相关基因的新型模型与免疫微环境特征相关，并可预测肺鳞状细胞癌的预后。
J Clin Lab Anal. 2022 Jan;36(1):e24135. doi: 10.1002/jcla.24135. Epub 2021 Nov 19.
4
Quantitative immunohistochemistry (IHC) analysis of biomarker combinations for human esophageal squamous cell carcinoma.人食管鳞状细胞癌生物标志物组合的定量免疫组织化学（IHC）分析
Ann Transl Med. 2021 Jul;9(13):1086. doi: 10.21037/atm-21-2950.
5
Identification of and expression as novel candidate biomarkers for predicting the benefit of immunotherapy in lung squamous cell carcinoma.鉴定并表达作为预测肺鳞状细胞癌免疫治疗获益的新型候选生物标志物。
Ann Transl Med. 2021 Jul;9(13):1081. doi: 10.21037/atm-21-2186.
6
Tumor mutation burden derived from small next generation sequencing targeted gene panel as an initial screening method.基于小范围二代测序靶向基因panel得出的肿瘤突变负荷作为一种初始筛查方法。
Transl Lung Cancer Res. 2020 Feb;9(1):71-81. doi: 10.21037/tlcr.2019.12.27.
本文引用的文献
1
Tumor mutational burden quantification from targeted gene panels: major advancements and challenges.基于靶向基因panel 的肿瘤突变负荷定量：主要进展与挑战
J Immunother Cancer. 2019 Jul 15;7(1):183. doi: 10.1186/s40425-019-0647-4.
2
Approach to evaluating tumor mutational burden in routine clinical practice.常规临床实践中评估肿瘤突变负荷的方法。
Transl Lung Cancer Res. 2018 Dec;7(6):678-681. doi: 10.21037/tlcr.2018.10.10.
3
Methods of measurement for tumor mutational burden in tumor tissue.肿瘤组织中肿瘤突变负荷的测量方法。
Transl Lung Cancer Res. 2018 Dec;7(6):661-667. doi: 10.21037/tlcr.2018.08.02.
4
Spotlight on tumor mutational burden in patients with non-small cell lung carcinoma.聚焦非小细胞肺癌患者的肿瘤突变负荷
Transl Lung Cancer Res. 2018 Dec;7(6):614-615. doi: 10.21037/tlcr.2018.08.06.
5
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.度伐利尤单抗化疗和放疗后用于 III 期非小细胞肺癌的总生存。
N Engl J Med. 2018 Dec 13;379(24):2342-2350. doi: 10.1056/NEJMoa1809697. Epub 2018 Sep 25.
6
Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer.帕博利珠单抗联合化疗用于鳞状非小细胞肺癌。
N Engl J Med. 2018 Nov 22;379(21):2040-2051. doi: 10.1056/NEJMoa1810865. Epub 2018 Sep 25.
7
PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project.PD-L1 免疫组织化学在真实临床样本中的可比性研究：Blueprint 阶段 2 项目的结果。
J Thorac Oncol. 2018 Sep;13(9):1302-1311. doi: 10.1016/j.jtho.2018.05.013. Epub 2018 May 22.
8
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.帕博利珠单抗联合化疗治疗转移性非小细胞肺癌。
N Engl J Med. 2018 May 31;378(22):2078-2092. doi: 10.1056/NEJMoa1801005. Epub 2018 Apr 16.
9
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden.纳武利尤单抗联合伊匹单抗治疗高肿瘤突变负荷肺癌。
N Engl J Med. 2018 May 31;378(22):2093-2104. doi: 10.1056/NEJMoa1801946. Epub 2018 Apr 16.
10
Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing.采用靶向下一代测序技术对非小细胞肺癌患者进行分析，明确了对抗程序性细胞死亡蛋白 1（PD-1）和抗程序性死亡配体 1（PD-L1）阻断治疗的反应的分子决定因素。
J Clin Oncol. 2018 Mar 1;36(7):633-641. doi: 10.1200/JCO.2017.75.3384. Epub 2018 Jan 16.
Zotero 插件